Did anyone listen to TSPT’s CC this morning on the Intermezzo driving study? Based on the price action today and the ambiguous data in TSPT’s PR this morning (http://finance.yahoo.com/news/Transcept-Pharmaceuticals-prnews-1322169261.html?x=0&.v=1 ), it looks like FDA approval is far from assured.